NPORT-EX 2 vcci-521.htm SCHEDULE OF INVESTMENTS AND NOTES

 
HATTERAS VC CO-INVESTMENT FUND II, LLC
 
 
(A Delaware Limited Liability Company)
 
 
SCHEDULE OF INVESTMENTS
 
 
March 31, 2021 (Unaudited)
 

 
Descriptions of Investment
Initial Investment Date
 
Cost
   
Fair Value
   
% of Members' Capital
 
                       
 
Private Company:
                   
 
Healthcare:
                   
 
Clinipace, Inc. (1)(2)(3)
                   
 
Raleigh, North Carolina
                   
 
100,158 shares of
                   
 
  Series I Preferred Stock
Sep. 2011
   
500,000
     
188,487
     
23.50
%
 
Total Healthcare
     
500,000
     
188,487
     
23.50
%
                             
 
Software:
                         
 
Kollective Technology.  (1)(2)(3)
                         
 
Sunnyvale, California
                         
 
1,740,151 shares of
                         
 
  Common Stock
Jul. 2010
   
730,193
     
295,826
     
36.88
%
                             
 
Posit Science Corporation (1)(2)(3)
                         
 
San Fransisco, California
                         
 
80,515 shares of
                         
 
  Common Stock
Dec. 2009
   
200,000
     
36,163
     
4.51
%
                             
 
Posit Science Corporation (1)(2)(3)
                         
 
San Fransisco, California
                         
 
21,669 shares of
                         
 
  Series AA Preferred Stock
Sep. 2010
   
11,893
     
9,283
     
1.16
%
 
Total Software
     
942,086
     
341,272
     
42.55
%
                             
 
Total Investments in Private Companies (United States)
   
1,442,086
     
529,759
     
66.05
%
                             
 
Short Term Investment:
                         
 
First American Treasury Obligations Fund - Class X, 0.02% (4)
   
372,343
     
372,343
     
46.42
%
 
Total Short Term Investment
     
372,343
     
372,343
     
46.42
%
                             
 
Liabilities in excess of Other Assets
             
(99,988
)
   
-12.47
%
                             
 
Members' Capital
           
$
802,114
     
100.00
%

 
(1) Non-income producing.
         
 
(2) Portfolio holdings are subject to substantial restrictions as to resale.
     
 
(3) Non-marketable securities
         
 
(4) Rate reported is 7-day yield reported as of March 31, 2021
     
             
 
The cost and fair value of restricted Private Company investments are $1,442,086 and $529,759, respectively.
 
             
See notes to financial statements.
         



The Fund classifies its assets into three levels based on the lowest level of input that is significant to the fair value measurement. The three-tier hierarchy distinguishes between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs) and to establish classification of fair value measurements for disclosure purposes. Various inputs are used in determining the value of the Fund’s investments.
The inputs are summarized in the three broad levels listed below:
Valuation of Investments

Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

Level 3 – significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)

   
Level 1
   
Level 2
   
Level 3
   
Total
 
Private Company1
                       
   Preferred Stock
 
$
-
   
$
-
   
$
197,770
   
$
197,770
 
   Common Stock
   
-
     
-
     
331,989
     
331,989
 
     Total
 
$
-
   
$
-
   
$
529,759
   
$
529,759
 
                                 
1 All private companies held in the Fund are level 3 securites. For a detailed break-out of private companies by industry classifications, please refer to the Schedule of Investments.
 

   
Preferred Stock
   
Common Stock
   
Total
 
Balance as of July 1, 2020
 
$
941,342
   
$
45,248
   
$
986,590
 
   Net Realized Gain/(Loss)
   
334,328
     
(566,003
)
   
(231,675
)
   Change in Unrealized Appreciation/(Depreciation)
   
75,034
     
564,682
     
639,716
 
   Transfers In/(Out) of Investment Categories*
   
(288,062
)
   
288,062
     
-
 
   Gross Purchases
   
-
     
-
     
-
 
   Gross Sales
   
(864,872
)
   
-
     
(864,872
)
Balance as of March 31, 2021
 
$
197,770
   
$
331,989
   
$
529,759
 
                         
* Transfers in or out of investment categories relfect changes in investment categories and are represented by their balance at the beginning of the period.
 


The following is a summary of quantitative information about significant unobservable input used for Level 3 fair value measurements for investments held as of March 31, 2021.
 
                 
                 
Type of Investment
 
Fair Value as of March 31, 2021
 
Valuation Technique
Unobservable Input
Multiple Used
Discount Used
Impact to Valuation from
Increase in Input
Common Stock
$
                            295,826
 
Discounted cash flows-M&A multiples
Discount rate
N/A
19.25%
Decrease
         
Forward M&A revenue multiple
3.03x
N/A
Increase
       
Discount
Discount for lack of marketability
N/A
26.50%
Decrease
Preferred Stock
 
                              188,487
 
Most recent transaction
Private financing
N/A
N/A
N/A
Common Stock
 
                                 36,163
 
Market comparable companies
Forward revenue multiple
2.84x
N/A
Increase
       
Discount
Discount for lack of marketability
N/A
48.17%
Decrease
Preferred Stock
 
                                   9,283
 
Market comparable companies
Forward revenue multiple
2.84x
N/A
Increase
       
Discount
Discount for lack of marketability
N/A
48.17%
Decrease
Total Investments
$
                            529,759
 
 
 
 
 
 

Investments in private companies are generally valued using most recent capitalization technique and market comparable companies techniques. The significant unobservable input used in the most recent capitalization technique is private financing. Two significant unobservable inputs used in the market comparable companies technique are the particular type of market multiple relied upon and a discount rate. Different types of multiples (e.g., forward revenue multiple) are relied upon across the Fund’s portfolio. A significant decrease in one of these multiples in isolation would result in a significantly lower fair value measurement. A significant increase in the discount rate in isolation would result in a significantly lower fair value measurement.
The significant unobservable inputs used in the fair value measurement of the Fund’s preferred and common stock are generally the financial results of privately held entities. If the financial condition of these companies were to deteriorate, or if market comparables were to fall, the value of the preferred stock or common stock in these private companies held by the Fund would be lower.
The Fund's valuation procedures have been approved by and are subject to continued oversight by the Fund's Board of Managers (the “Board”). The valuation procedures are implemented by the Adviser and the Fund's third party administrator, which report to the Board. For third-party information, the Fund's administrator monitors and reviews the methodologies of the various pricing services employed by the Fund.